Ensol Biosciences, Inc. manufactures and sells drugs. The firm develops BT·IT convergence technology (the core bioinformatics technology) such as in-silico genome analysis system, transcriptome analysis system, proteome analysis system and metabolome analysis system. It has been investing in developing bio-hydrogen energy, bio-environments, bio-foods and bio-cosmetics. The company was founded by Hae-Jin Kim on February 20, 2001 and is headquartered in Daejeon, South Korea.